CG Oncology

Today we are proud to announce the initiation of our Expanded Access Program (EAP) for cretostimogene grenadenorepvec in the U.S. for patients with Non-Muscle Invasive Bladder Cancer (#NMIBC) who are unresponsive to Bacillus Calmette-Guerin (BCG) and meet certain program eligibility criteria. The first patient has been dosed in the EAP, and enrollment is ongoing. 📄 Read the full release here: https://bit.ly/3Rv5a7C Healthcare providers and bladder cancer patients who are interested to learn more about CG Oncology’s EAP including eligibility criteria may visit www.clinicaltrials.gov, NCT06443944, or contact EAP@cgoncology.com. #BladderCancer #ClinicalTrials #UroOncology #Immunotherapy #PatientCare #DrugDevelopment #Immunotherapy #Therapeutics #CGOncology #cretostimogene

We’re on the ground at the 40th Annual European Association of Urology (EAU) Congress to share a series of key presentations and updates on our lead candidate, cretostimogene grenadenorepvec! Don’t miss Penn Medicine, University of Pennsylvania Health System’s Dr. Trinity Bivalacqua on Monday, March 24 presenting the latest clinical and translational data from BOND-003 Cohort C. More details: https://bit.ly/3DDA4ah #BladderCancer #Urology #UroOncology

Members of the CG Oncology team were honored to participate in the Bladder Cancer Advocacy Network's 2025 Spring Bladder Cancer Summit for Patients and Families in San Diego. Our team gained valuable insights into bladder cancer survivorship and they enjoyed discussing the latest breakthroughs in medical research, including CG Oncology's clinical trial program. Thank you to #BCAN for convening this important forum! - with CG Oncology's Kristen Scholz, Kristen M., & Elaine Harris and BCAN's Meri-Margaret Deoudes, CFRE

Members of the CG Oncology team are headed to Madrid, Spain for #EAU25. Join us as for a series of key presentations and updates, including late-breaking clinical and first translational data from BOND-003 Cohort C. Read more about our presentations: https://bit.ly/3DDA4ah European Association of Urology #BladderCancer #Urology #UroOncology

Today, Arthur Kuan, our Chairman & Chief Executive Officer, presented at the TD Cowen 45th Annual Health Care Conference in Boston. Thank you to #TDCowen for the opportunity to share an update on our progress developing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. - with Arthur Kuan, Ambaw Bellete, Corleen Roche, Chau Cheng, and Sarah Connors

Today, we announced that Arthur Kuan, our Chairman & Chief Executive Officer, is scheduled to present at the TD Cowen 45th Annual Health Care Conference in Boston, MA. To learn more, please visit: https://bit.ly/3CWAo3P #investors #healthcareconference #biotech

CG Oncology was delighted to attend the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco. At #ASCOGU25 our team learned about the latest high-impact science, multidisciplinary expertise, and evidence-based practices in GU cancer care. We also enjoyed connecting with urologists, medical oncologists and advocates and sharing insights on cretostimogene grenadenorepvec, our innovative, intravesically delivered oncolytic immunotherapy candidate for the treatment of Non-Muscle Invasive Bladder Cancer #NMIBC - with Elaine Harris, Gigi Palomera, DNP, Ambaw Bellete, Pat Keegan, MD, MPH, Vijay Kasturi, Kristen Scholz, and Shelja Patel, PharmD, RPh, BCMAS

This time last year, CG Oncology announced the closing of its Initial Public Offering, https://bit.ly/4h2uiNX. We appreciate the confidence that investors and other key stakeholders have in our ability to deliver a new and innovative bladder-sparing therapeutic for patients afflicted with bladder cancer. We take our work very seriously and we are grateful to have the resources, including from the recent follow-on equity offering, necessary to prepare for a BLA filing and ultimately, commercialization. 

At CG Oncology, we are inspired by Dr. Martin Luther King, Jr.’s incredible legacy. Dr. King’s leadership during the Civil Rights movement made a lasting impact on our country, and we strive to follow his example by building a diverse workforce representing people of different ethnicities, backgrounds and ideologies.  

Members of the CG Oncology team enjoyed meeting with investors, analysts and other members of the biotech industry during the 43rd annual J.P. Morgan Healthcare Conference in San Francisco this week. We were proud to share our progress developing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Thanks to everyone who met with us at #JPM. We appreciate your time, interest, and insights. 2025 is off to a good start! - with Arthur Kuan, Ambaw Bellete, Vijay Kasturi, Corleen Roche, Brian McGee, Chau Cheng, Jack Connelly, Lina C.